The €3M wall in medtech — and the distributor economics that break through it

Almost every medical device founder I meet hits the same wall somewhere between €2M and €4M in revenue. The product works. The clinical evidence is real. Reorders are coming in. And yet growth flattens, quarter after quarter, for reasons nobody on the team can quite name.

The instinct is to blame the market — the tender cycle, a slow quarter, a competitor discounting. Usually it’s none of those. The wall is structural, and it’s almost always the same structure: the distributor economics that got you to €3M are the exact economics that stop you scaling past it.

How the model helps you — right up until it doesn’t

In the early years, distributors are a gift. They give you reach you could never afford to build, local relationships with clinicians and procurement, and a variable cost base — you pay margin only when they sell. For a founder with more product than capital, handing 30–45% of revenue to a distributor in exchange for a market is a rational trade.

The problem is that the same deal contains a ceiling, and the ceiling is invisible until you hit it.

A distributor optimises for their portfolio, not yours. Your device is one of forty lines their reps carry. When it sells itself, they love it. The moment it needs real selling — a new indication, a clinical objection, a competitive tender — it drops down the rep’s priority list, because their time goes to whatever converts fastest. You don’t see this in a dashboard. You see it as “the market softened.”

The three numbers that tell you you’ve hit the wall

Before you change anything, measure. Three numbers usually expose the structural cap:

1. Revenue concentration by distributor. If your top two distributors are more than half your revenue, you don’t have a sales engine — you have two relationships, and both of them know it.

2. Effective margin after distributor and logistics cost. Founders quote gross margin on the device. What matters for scaling is what’s left after the channel takes its share and you fund the support the distributor doesn’t. It’s often 20 points lower than the number in the pitch deck.

3. Share of pull vs push. What fraction of sales came from clinician demand you created (pull) versus a rep pushing your line (push)? Pull scales. Push depends on someone else’s motivation.

If concentration is high, effective margin is thin, and pull is low, you’ve found your wall. It isn’t demand. It’s that you’ve outsourced the one thing you most need to control at this stage: the commercial motion.

The break-through move: earn back the commercial layer

You don’t fix this by firing your distributors. In tender-driven and clinician-led markets, they’re often carrying real regulatory and logistics weight you don’t want to rebuild. You fix it by taking back the parts of the commercial motion that compound — and leaving the distributor the parts that don’t.

In practice that means three shifts:

Own demand generation. The clinical evidence story, the KOL relationships, the market-access narrative, the tender strategy — these are yours, permanently. Build them in-house or with an executive, and feed the distributor warm demand instead of relying on their cold effort. A distributor selling into demand you created is a fulfilment partner. A distributor creating the demand is your ceiling.

Restructure the deal around behaviour you want. Flat margin rewards order-taking. Tiered margin, co-funded clinical activity, and protected territories tied to growth targets reward the selling you actually need. The economics should pay for pull, not just push.

Instrument the channel. You cannot manage what you cannot see. Sell-through data by account, not just sell-in to the distributor, turns “the market softened” into “these six accounts stalled and here’s why.” That’s a problem you can act on.

What changes when you do this

The founders who break the €3M wall don’t do it with a heroic quarter. They do it by changing what the business owns. Demand generation moves in-house and starts compounding. Effective margin recovers because you’re no longer subsidising a channel that isn’t selling. And revenue stops depending on two distributors’ goodwill.

None of this is a growth hack. It’s the unglamorous work of deciding which parts of your commercial engine are too important to rent — and building them into a system that stays with your team.

---

This is the kind of constraint the Scale Scorecard surfaces in five minutes. If revenue concentration or a missing commercial engine is your #1 driver, this is where the work starts.